Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date (Q26822717)

Katharine A. McNeill

series ordinal

2

1 reference

Howard A. Fine

series ordinal

3

1 reference

language of work or name

1 reference

15 February 2015

1 reference

1 reference

121

1 reference

PubMed

issue

4

1 reference

PubMed

page(s)

502-16

1 reference

PubMed

cites work

Genetics of adult glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Adjuvant chemotherapy in the treatment of high grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

10 questions about temozolomide and the treatment of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Malignant astrocytic glioma: genetics, biology, and paths to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Gene expression profiling of gliomas strongly predicts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Molecular subclassification of diffuse gliomas: seeing order in the chaos

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Chromosomal patterns in human malignant astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Advances in the genetics of glioblastoma: are we reaching critical mass?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Amplification and differential expression of members of the erbB-gene family in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Prognostic significance of c-Met expression in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A human brain tumor-derived PDGFR-alpha deletion mutant is transforming

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Proliferation of human malignant astrocytomas is dependent on Ras activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

PI3K/Akt/mTOR pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Mutations of the PIK3CA gene are rare in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

PTEN signaling pathways in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

PTEN enters the nuclear age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Emerging insights into the molecular and cellular basis of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

mTOR signaling in glioblastoma: lessons learned from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Akt and autophagy cooperate to promote survival of drug-resistant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Pten haploinsufficiency accelerates formation of high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The p53 gene and its role in human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Twenty years of p53 research: structural and functional aspects of the p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

IDH1 and IDH2: not your typical oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Revisiting the TCA cycle: signaling to tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Expanding chemical biology of 2-oxoglutarate oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Taxing sugar-sweetened beverages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

White matter disease in cerebral organic acid disorders: clinical implications and suggested pathomechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Cancer. Puzzling patterns of predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

G-cimp status prediction of glioblastoma samples using mRNA expression data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Glioblastoma: from molecular pathology to targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Imatinib mesylate in the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Continuous daily sunitinib for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Bevacizumab in glioblastoma--still much to learn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Amplified cellular oncogenes in neoplasms of the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Gain of function mutations in p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

Primary brain tumours in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

p53 mutations versus EGF receptor expression in giant cell glioblastomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

Different tumor-derived p53 mutants exhibit distinct biological activities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28968

7 January 2021

Identifiers

DOI

10.1002/CNCR.28968

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25250735

1 reference

Consolidated OpenCitations Corpus – April 2017